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Protein kinases are targets for drug development [1]. Dys-
regulation of kinase activity leads to various diseases [2],
e.g. cancer, inflammation, diabetes [1]. Human polo-like
kinase 1 (Plk1), a serine/threonine kinase, is a cancer-rel-
evant gene and a potential drug target which attracts
increasing attention in the field of cancer therapy. Plk1 is
a key player in mitosis and modulates entry into mitosis
and the spindle checkpoint at the meta-/anaphase transi-
tion. Plk1 overexpression is observed in various human
tumors, and it is a negative prognostic factor for cancer
patients [3].
The same catalytical mechanism and the same co-sub-
strate (ATP) lead to the problem of inhibitor selectivity. A
strategy to solve this problem is represented by targeting
the inactive conformation of kinases [2]. Kinases undergo
conformational changes between active and inactive con-
formation and thus an additional hydrophobic pocket is
created in the inactive conformation where the surround-
ing amino acids are less conserved [2].
A "homology model" of the inactive conformation of
Plk1 was constructed, as the crystal structure in its inactive
conformation is unknown. A crystal structure of Aurora A
kinase served as template structure. With this homology
model a receptor-based pharmacophore search was per-
formed using SYBYL7.3 software. The raw hits were fil-
tered using physico-chemical properties. The resulting hits
were docked using Gold3.2 software, and 13 candidates
for biological testing were manually selected.
Three compounds of the 13 tested exhibit anti-prolifera-
tive effects in HeLa cancer cells. The most potent inhibitor,
SBE13, was further tested in various other cancer cell lines
of different origins and displayed EC50 values between 12
μM and 39 μM. Cancer cells incubated with SBE13
showed induction of apoptosis, detected by PARP (Poly-
Adenosyl-Ribose-Polymerase) cleavage, caspase 9 activa-
tion and DAPI staining of apoptotic nuclei.
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